These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 18006752)

  • 1. Biomarkers in phase I oncology trials: signal, noise, or expensive distraction?
    Ratain MJ; Glassman RH
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6545-8. PubMed ID: 18006752
    [No Abstract]   [Full Text] [Related]  

  • 2. [Methodological approaches of clinical studies with targeted therapies].
    Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
    Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers in early clinical trials: the committed and the skeptics.
    Banerji U; de Bono J; Judson I; Kaye S; Workman P
    Clin Cancer Res; 2008 Apr; 14(8):2512; author reply 2513-4. PubMed ID: 18413847
    [No Abstract]   [Full Text] [Related]  

  • 4. Visualizing the landscape of selection biomarkers in current phase III oncology clinical trials.
    Sikorski R; Yao B
    Sci Transl Med; 2010 Jun; 2(34):34ps27. PubMed ID: 20519717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cancer biomarker problem.
    Sawyers CL
    Nature; 2008 Apr; 452(7187):548-52. PubMed ID: 18385728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Biomarkers for today and tomorrow in thoracic oncology].
    Barlesi F; Greillier L
    Rev Mal Respir; 2010 Apr; 27(4):289-90. PubMed ID: 20403538
    [No Abstract]   [Full Text] [Related]  

  • 8. [Immunohistochemical studies].
    Dietz A; Bosch F
    HNO; 2004 May; 52(5):468-70. PubMed ID: 15088091
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical biomarkers of kinase activity: examples from EGFR inhibition trials.
    Krause M; Baumann M
    Cancer Metastasis Rev; 2008 Sep; 27(3):387-402. PubMed ID: 18427731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standards for reporting prognostic tumor marker studies.
    Alonzo TA
    J Clin Oncol; 2005 Dec; 23(36):9053-4. PubMed ID: 16301590
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase 1 clinical trials in oncology.
    Rothschild BB; King NM
    N Engl J Med; 2005 Jun; 352(23):2451-3; author reply 2451-3. PubMed ID: 15944433
    [No Abstract]   [Full Text] [Related]  

  • 12. Novel designs and end points for phase II clinical trials.
    Adjei AA; Christian M; Ivy P
    Clin Cancer Res; 2009 Mar; 15(6):1866-72. PubMed ID: 19276272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers in cancer research and treatment: promises and challenges.
    Hainaut P; Plymoth A
    Curr Opin Oncol; 2011 Jan; 23(1):61. PubMed ID: 21321519
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase 1 clinical trials in oncology.
    Muggia FM
    N Engl J Med; 2005 Jun; 352(23):2451-3; author reply 2451-3. PubMed ID: 15948269
    [No Abstract]   [Full Text] [Related]  

  • 15. Ethical considerations in pediatric oncology phase I clinical trials according to The Belmont Report.
    Haylett WJ
    J Pediatr Oncol Nurs; 2009; 26(2):107-12. PubMed ID: 19190176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An exploratory survey of nurses' perceptions of phase I clinical trials in pediatric oncology.
    Chang A
    J Pediatr Oncol Nurs; 2008; 25(1):14-23. PubMed ID: 18187597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive and prognostic markers in cancer.
    Hayes D; Padnos SB
    Clin Adv Hematol Oncol; 2011 Feb; 9(2):130-2. PubMed ID: 22379660
    [No Abstract]   [Full Text] [Related]  

  • 18. Advances and challenges in the use of biomarkers in clinical trials.
    Chabner B
    Clin Adv Hematol Oncol; 2008 Jan; 6(1):42-3. PubMed ID: 18322440
    [No Abstract]   [Full Text] [Related]  

  • 19. Mechanisms linking physical activity with cancer.
    McTiernan A
    Nat Rev Cancer; 2008 Mar; 8(3):205-11. PubMed ID: 18235448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalizing cancer care: updates on head and neck cancer.
    de Souza JA; Cohen EE
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1219-22. PubMed ID: 19761425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.